Per our directory, Left Lane leads Series A and later growth rounds. It does not target pre-seed or seed—the firm focuses on companies with traction ready to scale, often in consumer and vertical software.

Left Lane Capital does not publicly disclose a standard check size. Our directory estimate, based on Series A and growth focus, suggests multi-million-dollar commitments sized for scaling—not micro-seed checks.

Left Lane Capital has offices in New York and London per its website. It invests in consumer and technology businesses globally, with portfolio companies across North America, Europe, and other markets.

Our directory tags consumer and marketplace. Left Lane publicly targets hyper-growth companies in e-commerce, health tech, vertical SaaS, and digital-first brands—often where data-driven customer relationships create defensibility.

Left Lane positions itself as a lead Series A and growth investor. Portfolio testimonials on leftlane.com cite founders choosing Left Lane term sheets for deep sector knowledge and hands-on scaling support.

Talkiatry (/startup/talkiatry) is the startup currently in our directory with Left Lane Capital listed as an investor. Left Lane's public portfolio includes additional consumer and health-tech companies not yet profiled here.

Founders with Series A–stage traction in consumer or vertical tech can engage through leftlane.com. Warm introductions from operators, bankers, or existing portfolio founders are typical; the firm emphasizes data-driven diligence.

We do not yet have a dedicated Left Lane Capital article. Our Talkiatry startup profile notes Left Lane participation where publicly attributed; watch for future NYC growth-equity coverage as the firm scales its portfolio.